

Metabolic Syndrome

Underlying Mechanisms and Drug Therapies

Edited by

Minghan Wang

Amgen, Inc., Thousand Oaks, California, USA



A JOHN WILEY & SONS, INC., PUBLICATION

Metabolic Syndrome

Metabolic Syndrome

Underlying Mechanisms and Drug Therapies

Edited by

Minghan Wang

Amgen, Inc., Thousand Oaks, California, USA



A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2011 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey
Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Metabolic syndrome : underlying mechanisms and drug therapies / edited by Minghan Wang.
p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-34342-5 (cloth)

1. Metabolic syndrome--Pathophysiology. 2. Metabolic syndrome--Chemotherapy. I. Wang, Minghan, 1966-

[DNLM: 1. Metabolic Syndrome X--drug therapy. 2. Metabolic Syndrome X--physiopathology. WK 820 M58695 2011]

RC662.4.M53 2011

616.3'99--dc22

2010019505

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

Contents

Introduction	ix
---------------------	-----------

Minghan Wang

Contributors	xi
---------------------	-----------

Part One The Physiology of Metabolic Tissues Under Normal
 and Disease States

1. Gut as an Endocrine Organ: the Role of Nutrient Sensing in Energy Metabolism	3
--	----------

Minghan Wang

2. Central Glucose Sensing and Control of Food Intake and Energy Homeostasis	29
---	-----------

Lourdes Mounien and Bernard Thorens

3. Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus	53
--	-----------

Taly Meas and Pierre-Jean Guillausseau

4. Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae	73
---	-----------

*Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor,
and Peter Zahradska*

5. Hepatic Metabolic Dysfunctions in Type 2 Diabetes: Insulin Resistance and Impaired Glucose Production and Lipid Synthesis	133
---	------------

Ruojing Yang

6. Energy Metabolism in Skeletal Muscle and its Link to Insulin Resistance 157

Minghan Wang

Part Two Metabolic Diseases and Current Therapies

7. Mechanisms and Complications of Metabolic Syndrome 179

Minghan Wang

8. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL 199

Margrit Schwarz and Jae B. Kim

9. Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery 235

Devan Marar, Shobha H. Ganji, Vaijinath S. Kamanna, and Moti L. Kashyap

10. Current Antidiabetic Therapies and Mechanisms 253

Minghan Wang

Part Three Drug Targets for Antidiabetic Therapies

11. GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies 281

Remy Burcelin, Cendrine Cabou, Christophe Magnan, and Pierre Gourdy

12. Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes 327

C.H.S. McIntosh, S.-J. Kim, R.A. Pederson, U. Heiser, and H.-U. Demuth

13. Sodium Glucose Cotransporter 2 Inhibitors 359

Margaret Ryan and Serge A. Jabbour

14. Fibroblast Growth Factor 21 as a Novel Metabolic Regulator 377

Radmila Micanovic, James D. Dunbar, and Alexei Kharitononkov

15. Sirtuins as Potential Drug Targets for Metabolic Diseases 391

Qiang Tong

16. 11 β -Hydroxysteroid Dehydrogenase Type 1 as a Therapeutic Target for Type 2 Diabetes **423**

Clarence Hale and David J. St. Jean, Jr.

17. Monoclonal Antibodies for the Treatment of Type 2 Diabetes: A Case Study with Glucagon Receptor Blockade **459**

Hai Yan, Wei Gu, and Murielle Veniant-Ellison

Part Four Lessons Learned and Future Outlook

18. Drug Development for Metabolic Diseases: Past, Present and Future **471**

Minghan Wang

Index **489**

Introduction

It has been more than 20 years since Reaven first introduced the concept of syndrome X or insulin resistance syndrome to describe the clustering of several cardiovascular risk factors. The concept has evolved over the years and is now commonly referred to as metabolic syndrome, which covers the individual metabolic abnormalities of obesity, insulin resistance, hyperglycemia, dyslipidemia (high triglycerides and low HDL), and hypertension. Patients with metabolic syndrome have increased risk of developing cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Despite the debates surrounding the existence and definition of metabolic syndrome, the concept has been useful in understanding the interconnections of the various risk factors that are common in a large population of patients and thereby managing the overall disease risk. From the drug discovery standpoint, all the components of metabolic syndrome are therapeutic targets for the treatment of CVD and T2DM to reduce comorbidities and overall mortality.

While there is a wealth of information concerning the clinical features and mechanisms of metabolic syndrome, putting them in the physiological context relevant to the development of therapeutics is essential for drug discovery. The goal of this book is to provide comprehensive understanding of the molecular and physiological abnormalities associated with metabolic syndrome and the therapeutic strategies for drug development. Part One is devoted to gaining an integrated understanding of the metabolic abnormalities at the tissue and pathway levels that are associated with disease states. In Part Two, metabolic syndrome is discussed at the physiological level and current therapies are summarized. These sections help lay the foundation to identify pathways and molecular targets for the development of antidiabetic therapies in Part Three. Since more than 80% type 2 diabetic patients have metabolic syndrome, a large portion of this book is devoted to antidiabetic therapies. Finally, the successes and failures in developing antidiabetic and cardiovascular drugs and lessons learned are discussed in Part Four. Although the chapters are contributed by different authors, the organization and the content of the book have been carefully designed so that the information is presented systematically. In the meantime, each chapter independently covers a subarea of metabolic or drug discovery topics, the reader has the flexibility to gain information on a specific tissue, pathway, or target in a time-efficient manner. Despite the exciting advances that have been made in developing antidiabetic and CVD therapies in the past several

decades, drug discovery in these areas continues to be a challenge. I hope this book will help the reader better understand the exciting science behind metabolic drug discovery and development and develop a greater appreciation of the complexity of metabolic syndrome as well as the treatment strategies.

MINGHAN WANG

Contributors

Remy Burcelin, Ranguel Institute of Molecular Medicine, INSERM U858, Toulouse, France

Cendrine Cabou, Ranguel Institute of Molecular Medicine, INSERM U858, Toulouse, France

Vanessa DeClercq, Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Canada; Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research Centre, Winnipeg, Canada

H.-U. Demuth, Probiodrug AG, Biocenter, Halle (Saale), Germany

James D. Dunbar, BioTechnology Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA

Shobha H. Ganji, Department of Veterans Affairs Healthcare System, Atherosclerosis Research Center, Long Beach, CA, USA; Department of Medicine, University of California, Irvine, CA, USA

Pierre Gourdy, Ranguel Institute of Molecular Medicine, INSERM U858, Toulouse, France

Wei Gu, Department of Metabolic Disorders, Amgen, Inc., Thousand Oaks, CA, USA

Pierre-Jean Guillausseau, APHP, Department of Internal Medicine B, Hôpital Lariboisière, Paris, France; Université Paris 7, Paris, France

Clarence Hale, Department of Metabolic Disorders, Amgen, Inc., Thousand Oaks, CA, USA

U. Heiser, Probiodrug AG, Biocenter, Halle (Saale), Germany

Ryan Hunt, Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Canada; Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research Centre, Winnipeg, Canada

Serge A. Jabbour, Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA

Vaijinath S. Kamanna, Department of Veterans Affairs Healthcare System, Atherosclerosis Research Center, Long Beach, CA, USA; Department of Medicine, University of California, Irvine, CA, USA

Moti L. Kashyap, Department of Veterans Affairs Healthcare System, Atherosclerosis Research Center, Long Beach, CA, USA; Department of Medicine, University of California, Irvine, CA, USA

Alexei Kharitononkov, BioTechnology Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA

Jae B. Kim, Global Development, Amgen, Inc., Thousand Oaks, CA, USA

S.-J. Kim, Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, Canada; Diabetes Research Group, Life Sciences Institute, University of British Columbia, Vancouver, Canada

Christophe Magnan, INSERM U858, Toulouse, France; University Paris Diderot, CNRS, Paris, France

C.H.S. McIntosh, Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, Canada; Diabetes Research Group, Life Sciences Institute, University of British Columbia, Vancouver, Canada

Devan Marar, Department of Veterans Affairs Healthcare System, Atherosclerosis Research Center, Long Beach, CA, USA; Department of Medicine, University of California, Irvine, CA, USA

Radmila Micanovic, BioTechnology Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA

Taly Meas, APHP, Department of Internal Medicine B, Hôpital Lariboisière, Paris, France; Université Paris 7, Paris, France

Lourdes Mounien, Department of Physiology, University of Lausanne, Lausanne, Switzerland; Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

R.A. Pederson, Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, Canada; Diabetes Research Group, Life Sciences Institute, University of British Columbia, Vancouver, Canada

Margaret Ryan, Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA

Margrit Schwarz, Department of Metabolic Disorders, Amgen, Inc., South San Francisco, CA, USA

David J. St. Jean, Jr., Department of Medicinal Chemistry, Amgen, Inc., Thousand Oaks, CA, USA

Danielle Stringer, Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Canada; Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research Centre, Winnipeg, Canada

Carla G. Taylor, Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Canada; Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research Centre, Winnipeg, Canada

Bernard Thorens, Department of Physiology, University of Lausanne, Lausanne, Switzerland; Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

Qiang Tong, USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, USA

Murielle Veniant-Ellison, Department of Metabolic Disorders, Amgen, Inc., Thousand Oaks, CA, USA

Minghan Wang, Metabolic Disorders Research, Amgen, Inc., Thousand Oaks, CA, USA

Hai Yan, Department of Protein Science, Amgen, Inc., Thousand Oaks, CA, USA

Ruojing Yang, Department of Metabolic Disorders – Diabetes, Merck Research Laboratories, Rahway, NJ, USA

Peter Zahradka, Department of Physiology, University of Manitoba, Winnipeg, Canada; Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Canada; Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research Centre, Winnipeg, Canada